Panbela Therapeutics to Receive a Total Up to $9.5 Million for Divestiture of Assets within Eflornithine (DFMO) Pediatric Neuroblastoma Program to US WorldMeds

Stock Information for Panbela Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Panbela Therapeutics Inc.

Panbela Provides Business Update and Reports Q3 2024 Financial Results
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center
Panbela Provides Business Update and Reports Q2 2024 Financial Results
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
Panbela Provides Business Update and Reports Q1 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.